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Abstract
Background: The vasoconstricting peptide endothelin-1 has been proposed to be a marker of cardiovascular
disease. Our aim was to investigate whether circulating endothelin-1 levels predict coronary heart disease (CHD)
in Sweden.
Methods: In 2002–2005, 2816 adult participants (30–74 years) were randomly selected from two municipalities in
south-western Sweden. Cardiovascular risk factors and endothelin-1 levels were assessed at baseline, and incident
CHD was followed-up in all participants through 2011. After exclusion of 50 participants due to known CHD at
baseline and 21 participants because of unsuccessful analysis of endothelin-1, 2745 participants were included in
the study. In total, 72 CHD events (52 in men and 20 in women) were registered during the follow-up time.
Results: We showed that baseline circulating endothelin-1 levels were higher in women with incident CHD than in
women without CHD (3.2 pg/ml, SE: 0.36 vs 2.4 pg/ml, SE: 0.03, p = 0.003) whereas this difference was not observed
in men (2.3 pg/ml, SE: 0.16 vs 2.3 pg/ml, SE: 0.04, p = 0.828). An age-adjusted Cox proportional regression analysis
showed an enhanced risk of CHD with increasing baseline endothelin-1 levels in women (hazard ratio (HR) = 1.51,
95 % CI = 1.1–2.1, p = 0.015) but not in men (HR = 0.98, 95 % CI = 0.8–1.2, p = 0.854). Furthermore, the predictive
value of endothelin-1 for incident CHD in women was still significant after adjustments for age, HOMA-IR,
apolipoprotein (apo)B/apoA1 and smoking (HR = 1.53, CI = 1.1–1.2, p = 0.024).
Conclusion: Circulating endothelin-1 levels may predict CHD in women.
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Background
Coronary heart disease (CHD) refers to a wide spectrum
of illnesses including coronary atherosclerosis, myocardial
infarction and post-infarct heart failure [1]. CHD is one of
the leading causes of mortality among men and women
causing almost 1.8 million deaths per year in Europe [2].
Endothelin-1, which is elevated in endothelial dysfunction,
has been proposed to be a marker of cardiovascular dis-
ease [3]. Thus, measurements of endothelin-1 might offer
insight into subclinical stages of CHD and guide clinicians
when to initiate primary and secondary prevention [4].
Circulating endothelin-1 levels have been shown to
increase in patients with advanced atherosclerosis and
coronary artery disease progression [5, 6]. Moreover,
earlier studies adopting a cross-sectional or retrospective
study design demonstrated that circulating endothelin-1
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levels were associated with CHD in women of all ages
while this association was only observed in older
men, thus, suggesting a predictive role of circulating
endothelin-1 for future CHD primarily in women [6–8]. A
recent prognostic observational study in selected patients
showed a predictive role of circulating endothelin-1 levels
on the first manifestations of atherosclerotic disease [9].
Here, we performed a longitudinal population-based study
of the Vara-Skövde cohort [10] to test the hypothesis that




The Vara-Skövde cohort has been previously described
[10]. Briefly, between 2002 and 2005 a cohort based on a
random age- and sex-stratified sample of subjects aged
30–74 years residing in these two municipalities was
recruited. The participation rate at baseline was 76 %
and information with regard to the CHD outcome was
surveyed through 2011 (Fig. 1). Standard questionnaires
were used to gain information on previous hospitalisa-
tions relevant for our hypothesis, leisure time physical
activity, smoking habits, and alcohol habits [10]. In total,
2816 subjects were randomly selected for screening; of
these, 50 were excluded because they displayed CHD at
baseline and a further 21 individuals were excluded be-
cause of unsuccessful endothelin-1 measurements. Thus,
2745 participants were included in the present study.
Measurements, blood sampling and analyses
The procedures of the investigation have been described
previously [11]. Briefly, participants arrived at the study
centre in the morning after fasting overnight. Body
weight and height were measured with participants in
light clothing and without shoes. Body mass index
(BMI) was calculated as weight (kg) divided by height
squared (m2). Waist circumference was measured be-
tween the lowest rib margin and the iliac crest and hip
circumference at the largest circumference between
waist and thighs. Fasting blood samples were drawn
and standard resting blood pressure was measured
twice 1 min apart with subjects in a supine position
with the arm adjusted to the heart level. The mean of
two readings was used for further analyses, hypertension
was defined in accordance with international expert guide-
lines (ESC/ESH) [12] and known hypertension was con-
sidered as ongoing treatment against high blood pressure.
HOMA-IR was estimated to get an assessment of insulin
sensitivity [13]. The participants were characterised with
respect to diabetes mellitus in accordance with current
recommendations from EASD/WHO [14]. Further ana-
lyses included apolipoprotein B/apolipoprotein A1 (apoB/
apoA1), high-density lipoprotein (HDL), low-density lipo-
protein (LDL), testosterone, estradiol, cholesterol, and
high sensitivity C-reactive protein (hs-CRP) using stand-
ard methods [15–17]. The QuantiGlo Chemiluminescent
ELISA for Human endothelin-1 from R&D systems
(Minneapolis, MN, USA) was used for the quantita-
tive determination of serum endothelin-1 concentra-
tions (intra-assay precision: CV % 3.4; inter-assay
precision: CV % 9.1).
Ethics
This study was approved by the local ethics committee
at the University of Gothenburg (Dnr 199–01) and all
participants gave signed informed consent in accordance
with the Declaration of Helsinki.
Follow-up
All participants were followed from the baseline examin-
ation until first CHD event or death, or otherwise until
Fig 1 Schematic overview of study design and follow-up of the study. CHD; coronary heart disease, ET-1; endothelin-1, PCI; percutaneous coronary
intervention, CABG; coronary artery bypass grafting
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December 31, 2011. All events were retrieved by data
linkage with the Swedish Cause of Death and Hospital
Discharge Registers, which are a reliable validated alter-
native to revised hospital discharge and death certificates
[18, 19]. The outcome considered in this study was
CHD defined as non-fatal myocardial infarction (ICD10
code I21), percutaneous coronary intervention (PCI)
and/or coronary artery bypass grafting (CABG) or fatal
CHD (ICD10 codes I21-I23 and I25) [20].
Statistical methods
Standard methods were used for descriptive statistics.
Linear regression models were used to investigate the as-
sociation between endothelin-1 and continuous variables
while differences between means in continuous variables
were analysed by general linear models. Kaplan-Meier
survival curves for tertiles of endothelin-1 concentrations
were analysed to decide the feasibility of analysis with Cox
regressions. After controlling for proportionality, Cox pro-
portional hazard regressions were used to investigate the
associations between circulating endothelin-1 levels and
CHD. Theoretical multivariate models were used to assess
interactions and to estimate the roles of possible con-
founders as considered by stratification, and by multivari-
ate analyses. The selection of variables for adjustment was
based on established risk factors for CHD, as well as
apparent correlations with endothelin-1. Differences be-
tween men and women were addressed in stratified ana-
lyses, as well as in combined analyses using calculations of
interaction terms as a statistical tool. All analyses were
two-sided, and p < 0.05 was considered statistically signifi-
cant. SPSS Base Systems for Macintosh 18.0 was used for
data analyses.
Availability of data
All the information is stored in databases. More de-
tailed information can be retrieved after contacting
the PI of the study (Professor Ulf Lindblad email-
ulf.lindblad@allmed.gu.se).
Results
During the follow-up time (8 ± 1.3 years), 72 events of
incident CHD (52 in men and 20 in women) were regis-
tered in the Swedish Hospital Discharge Register; of
these, 19 events (14 in men and 5 in women) were fatal
according to the Swedish Cause of Death Register. Thus,
the event rate of incident CHD was 2.6 per 1000 person
years (men 4.9 per 1000 person years; women 1.9 per
1000 person years). In total, 88 of the 2745 participants
died during the follow-up time.
Established risk factors and incident CHD
Clinical characteristics for men and women with or with-
out incident CHD are shown in Table 1. As expected, age,
waist hip ratio (WHR), LDL, apoB/apoA1, systolic and
diastolic blood pressure were significantly different be-
tween participants with or without incident CHD. Choles-
terol, hs-CRP and HOMA-IR only differed in men with or
without incident CHD. Hypertension and type 2 diabetes
were more common in the group with incident CHD for
both men and women. However, BMI, HDL, serum testos-
terone, serum estradiol, alcohol consumption, current
smoking and performing a low level of physical activity
were similar in participants irrespective of incident CHD.
Treatment with β-blockade against high blood pressure
was significantly more frequent in women who developed
CHD compared with women without incident CHD while
other medications did not significantly differ between the
groups. Other indications for treatment with β-blockade
were irregular heartbeat (2 men, 10 women); headache or
migraine (1 men, 6 women); and tremor (3 men, 1
woman). Participants reporting these indications were all
in the group not developing CHD.
Associations between clinical variables and circulating
endothelin-1 levels at baseline
Circulating endothelin-1 levels were lowest at age 30–39
years and increased significantly at age 40–49 years for
both men and women; however, endothelin-1 levels then
declined in a stepwise fashion in men (p = 0.003) (Fig. 2a)
but remained constant in women (Fig. 2b). Circulating
endothelin-1 levels were similar in participants with or
without hypertension (women: 2.4 pg/ml, SE: 0.04 vs
2.5 pg/ml, SE: 0.10, p = 0.801; men: 2.3 pg/mL, SE: 0.04
vs 2.3 pg/ml, SE: 0.09, p = 0.434). Linear regression ana-
lyses were used to explore the association of circulating
endothelin-1 levels with other clinical variables (Table 2).
Circulating endothelin-1 levels were associated with
both insulin resistance (HOMA-IR) and apoB/apoA1 ra-
tio in men whereas no such associations were observed
in women (Table 2). Furthermore, circulating testoster-
one levels were associated with circulating endothelin-1
levels in men (Table 2). Finally, HDL cholesterol showed
a positive association with circulating endothelin-1 levels
in women.
Circulating endothelin-1 levels and incident CHD
Circulating levels of endothelin-1 at baseline were not
different between men with or without incident CHD
in the follow-up period. By contrast, circulating
endothelin-1 levels at baseline in women with CHD
at follow-up were significantly higher than in women
without incident CHD (Fig. 2c). In women, the age at
the CHD event ranged between 44 and 82 years and
19 out of 20 women were postmenopausal (≥55 years
old) when they got their event.
Women showed a strong association between higher
circulating levels of endothelin-1 and CHD after
Daka et al. BMC Cardiovascular Disorders  (2015) 15:146 Page 3 of 8
adjustment for age (HR = 1.51 CI: 1.1–2.1 p = 0.015), but
this association was not significant in men (HR = 0.98, CI
0.8–1.2, p = 0.854) (Table 3). The association between
endothelin-1 levels and CHD in women also remained sig-
nificant after adjusting for age, HOMA-IR, apoB/apoA1
and smoking habits (HR = 1.51 CI 1.1–2.1 p = 0.024)
(Table 3). Further, in women the association between
endothelin-1 levels and CHD remained significant after
adjustment for age in combination with WHR, BMI,
LDL-cholesterol, HDL-cholesterol, hypertension, CRP,
triglycerides or medications (data not shown). Kaplan-
Meier survival curves showed no significant difference in
CHD event-free time in men depending on their circulat-
ing endothelin-1 concentrations (Fig. 3a). However, the
curves showed significantly shorter CHD event-free time
for women in the highest tertile of circulating endothelin-
1 concentrations when compared with women in the two
lower tertiles (p = 0.002) (Fig. 3b). Finally, an interaction-
term assessing the relationship between endothelin-1 and
sex was significant (p = 0.011).
Table 1 Baseline characteristics of adult residents with and without incident CHD during follow-up in the Vara-Skövde cohort
Men Women
All N = 1350 No CHD N = 1298 CHD N = 52 P-value All N = 1395 No CHD N = 1375 CHD N = 20 P-value
Mean ± SD Mean ± SD
Age (yrs) 47.3±11 46.7 ± 11 61.2±11 <0.001 47.7±12 47.4±12 63.9±11 <0.001
WHR 0.9±0.1 0.9±0.1 1.0±0.1 <0.001 0.8±0.1 0.8±0.1 0.9±0.1 0.004
BMI (kg/m2) 26.9±4 26.8±4 27.4±3 0.200 26.8±5 26.8±5 27.8±4 0.661
HOMA-IR 1.6±1.3 1.6±1.3 2.4±1.8 <0.001 1.5±1.6 1.5±1.6 2.1±1.7 0.073
S-LDL (mmol/l) 3.4 ± 0.9 3.4 ± 0.9 3.9 ± 0.9 <0.001 3.2 ± 0.9 3.1 ± 0.9 3.8 ± 1.1 0.001
S-HDL (mmol/l) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 0.916 1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.4 0.164
S-Cholesterol (mmol/l) 5.4 ± 1 5.4 ± 1 5.7 ± 1 0.018 5.3 ± 1.1 5.2 ± 1 5.4 ± 1.2 0.331
ApoB/apoA1 0.6 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.002 0.5 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.021
S-Triglycerides (mmol/l) 1.5 ± 0.9 1.4 ± 0.9 1.8 ± 1.1 0.018 1.1 ± 0.6 1.1 ± 0.6 1.4 ± 0.9 0.003
Hs-CRP (mg/l) 2.4 ± 5.8 2.2 ± 4.2 6.1 ± 21 <0.001 2.8 ± 4.6 2.8 ± 4.6 3.2 ± 3.9 0.675
Systolic blood pressure (mmHg) 124 ± 16 123 ± 15 138 ± 19 <0.001 119 ± 18 119 ± 18 143 ± 20 <0.001
Diastolic blood pressure (mmHg) 72 ± 10 72 ± 10 78 ± 12 <0.001 69 ± 10 68 ± 10 77 ± 10 <0.001
Alcohol consumption (g/week) 62 ± 108 62 ± 108 55 ± 91 0.666 31 ± 43 31 ± 44 20 ± 36 0.278
S-Testosterone (nmol/l) 14 ± 4.3 14 ± 4.3 13 ± 4.7 0.147 1.3 ± 1.3 1.3 ± 1.3 1.1 ± 0.5 0.524
S-Estradiol (nmol/l) 125 ± 37 125 ± 37 126 ± 40 0.875 304±381 305 ± 383 221 ± 50 0.314
N (%) N (%)
Hypertension 183 (14) 165 (13) 22 (42) <0.001 204 (14) 192 (14) 12 (57) <0.001
Type 2 diabetes 78 (5.7) 66 (5) 12 (23) <0.001 65 (4.6) 61 (4.4) 4 (19) 0.004
Daily smoking 214 (16) 201 (15) 13 (25) 0.068 288 (21) 282 (20) 6 (29) 0.364
Low physical activity 521 (38) 500 (40) 21 (45) 0.742 384 (27) 382 (29) 2 (10) 0.088
Medication
ARB 14 (1.0) 13 (1.0) 1 (1.9) 0.886 13 (0.9) 13 (1.0) 0 (0) 0.999
ASA 31 (2.2) 27 (2.1) 4 (7.7) 0.991 34 (2.4) 31 (2.2) 3 (14) 0.426
Statin 25 (1.8) 22 (1.7) 3 (5.8) 0.673 42 (2.9) 38 (2.7) 4 (19) 0.247
β-Blocker 64 (4.7) 58 (4.4) 6 (11.5) 0.830 89 (6.3) 80 (5.8) 9 (43) 0.007
ACE inhibitor 24 (1.8) 21 (1.6) 3 (5.8) 0.716 29 (2) 26 (1.9) 3 (14) 0.166
Metformin 14 (1.0) 13 (1.0) 1 (1.9) 0.992 19 (1.3) 18 (1.3) 1 (4.8) 0.988
HRT - - - - 247 (17) 238 (17) 9 (43) 0.434
All means are adjusted
All means are adjusted for differences in age. CHD: coronary heart disease; WHR: waist hip ratio (missing 10/2745); BMI: body mass index (missing 3/2745); HOMA-IR:
homeostatic model assessment of insulin resistance (missing 39/2745); LDL: low-density lipoprotein (missing 2/2745); HDL: high-density lipoprotein (missing 2/2745);
ApoB/apoA1: apolipoprotein B/apolipoprotein A1 (missing 4/2745), hs-CRP: high sensitivity c-reactive protein (missing 2/2745); testosterone (missing 135/2745); estradiol
(missing 30/2745); type 2 diabetes (missing 2/2745); physical activity (missing 91/2745); ARB: angiotensin II receptor blockers; ASA: acetyl-salicylic acid; ACE inhibitors:
angiotensin converting enzyme inhibitor; HRT: hormone replacement therapy. 12 g alcohol is equivalent to approximately 1 glass of wine (12–15 cl) or 1 small beer
(33 cl) (missing 126/2745). Differences in continuous variables were investigated using general linear models. Differences in dichotomous variables were analysed using
logistic regression analyses
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Discussion
In this large observational Swedish study, increased
circulating endothelin-1 levels were associated with inci-
dent CHD in women but not in men. This was inde-
pendent of other risk factors for CHD and circulating
levels of estradiol. This suggests that endothelin-1 may
be an important independent predictor of CHD risk in
woman. To our knowledge, this is the first time a study
prospectively shows the predictability of circulating
endothelin-1 levels for incident CHD in women.
Our main observation suggests sex-differences in the
association between endothelin-1 and the outcome in
our population, and this is also supported by a
Fig 2 Circulating concentrations of endothelin-1 at baseline separated by age in the Vara-Skövde Cohort in (a) men and (b) women. c Endothelin-1
levels at baseline comparing participants with incident CHD (men n = 52, women n = 20) and participants without coronary heart disease (CHD) (men
n = 1307, women n = 1386) at the follow-up. General linear model was used in statistical analyses, mean ± SEM
Table 2 Associations between circulating endothelin-1 levels
and selected variables at baseline in men and women from the
Vara-Skövde cohort
Men (n = 1350) Women (n = 1395)
β P β P
Age 0.029 0.290 0.090 0.001
BMI 0.025 0.343 0.015 0.563
WHR 0.023 0.237 0.001 0.999
HOMA-IR 0.066 0.016 0.031 0.262
Systolic BP 0.026 0.392 −0.029 0.386
Diastolic BP 0.012 0.663 −0.010 0.854
S-HDL 0.010 0.695 0.065 0.015
S-LDL 0.030 0.154 0.040 0.354
ApoB/apoA1 −0.064 0.018 0.001 0.999
Triglycerides 0.029 0.289 −0.018 0.697
CRP −0.020 0.437 0.015 0.542
Glucose 0.026 0.352 −0.014 0.618
LTPA −0.017 0.541 0.022 0.432
Smoking habits 0.007 0.776 0.018 0.524
Testosterone −0.055 0.048 0.006 0.816
Estradiol 0.001 0.990 0.005 0.861
Age-adjusted linear regression analysis to investigate the association between
concentrations of endothelin-1 and factors related to coronary heart disease
HOMA-IR homeostatic model assessment of insulin resistance, BMI body mass
index, WHR waist/hip ratio, BP blood pressure, HDL high-density lipoprotein,
LDL low-density lipoprotein, ApoB/apoA1 apolipoprotein B/apolipoprotein A1,
CRP C-reactive protein, LTPA leisure time physical activity
Table 3 Predictive value of baseline circulating endothelin-1
levels on CHD in men and women in the Vara-Skövde cohort
Men (n = 1350) Women (n = 1395)
HR CI p HR CI p
Crude
0.98 0.8–1.2 0.818 1.64 1.2–2.3 0.003
Adjusted for age
0.98 0.8–1.2 0.854 1.51 1.1–2.1 0.015
Adjusted for age, HOMA-IR, apoB/apoA1 and smoking
0.88 0.7–1.1 0.272 1.53 1.1–2.1 0.024
Cox-regression analysing the hazard ratio for CHD during follow-up time for
changes of endothelin-1 concentrations with 1 pg/ml
HR hazard ratio, CI confidence interval, ApoB/apoA1 apolipoprotein B/
apolipoprotein A1, HOMA-IR homeostatic model assessment of
insulin resistance
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significant interaction term. However, no association be-
tween circulating levels of estradiol and endothelin-1
was found. Earlier epidemiological and experimental
studies have shown that exogenous estradiol decreases
endothelin-1 levels whereas testosterone levels have
been shown to correlate positively with circulating
endothelin-1 levels [21, 22]. Similarly, women receiving
hormone replacement therapy in the Rancho Bernardo
cohort displayed lower circulating endothelin-1 levels
and administration of estrogen promotes vasodilation in
humans and in experimental animals [7, 23, 24]. In
addition, the Rancho Bernardo study showed an associ-
ation between CHD and endothelin-1 in older men [7].
The current study did not confirm this finding, likely be-
cause of the younger age of the participants and a low
number of CHD events in the population (2.6 % in men,
1.4 % in women). Interestingly, reduced circulating
endothelin-1 levels were observed in men over 50 years
old. This observation needs to be confirmed in larger
studies.
As expected, a number of baseline characteristics dif-
fered between participants who developed CHD and
those who remained healthy during the follow-up, and
some of these traits also showed associations with circu-
lating endothelin-1 levels at baseline. Interestingly, these
variables differed between men and women. In agree-
ment with earlier results, testosterone levels corre-
lated with endothelin-1 concentrations in men as
discussed above [21] and HOMA-IR also correlated
with endothelin-1 levels in men [25]. Moreover, apoB/
apoA1 was negatively associated with endothelin-1
levels in men, which was surprising, but currently lit-
tle is known about this correlation. The associations
between age and endothelin-1 levels in women con-
firm the results from previous investigations [26].
However, the positive correlation between endothelin-
1 and HDL in women was unexpected and suggests
that endothelin-1 may be beneficial for HDL metabol-
ism. To our knowledge, this association has not been
observed previously, and should be investigated fur-
ther. The main observation that endothelin-1 predicts
CHD in women was not affected when adjusting for
clinical traits that differed between the groups. Further-
more, an increase in circulating endothelin-1 concentra-
tions in participants diagnosed with hypertension was not
observed in this study, which is in line with previous ob-
servations [27], but in contrast with other observations
[28]. Different expression of endothelin-1 receptors in vas-
cular territories of the human body [29] may underlie the
link between endothelin-1 and coronary outcome and the
lack of an association between endothelin-1 and systemic
blood pressure.
Further, 43 % of women with incident CHD and 5.8 %
of women who remained healthy during follow-up were
treated with β-blockade for hypertension at baseline.
Although earlier studies report that β-blockade does not
affect calf blood flow in patients with chronic stable inter-
mittent claudication [30], a small study suggested that β-
blockade may be related to worsening of peripheral blood
flow [31]; however, very little has been published on the
effect of β-blockade on the microcirculation. We suggest
that this possibility should be elucidated in future studies.
Strengths and limitations
Some strengths and weaknesses of this survey need to
be mentioned. Advantages of this study include the high
participation rate, the unselected study population and
the prospective design allowing us to investigate the dir-
ection of the observed associations. However, a weakness
is the low number of CHD events and the results need
to be confirmed in larger population samples. Thus, the
Fig 3 Kaplan-Meier survival plots comparing time to the first
coronary heart disease (CHD) event between participants with the
highest tertile of endothelin-1 (ET-1) and the remaining population
in (a) men (highest tertile n = 453, two lower tertiles combined
n = 906) and (b) women (highest tertile n = 469, two lower tertiles
combined n = 938). + = Censored
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use of multivariate Cox regression analysis in subgroups
conveys risks to over interpret the associations, but the
predefined hypothesis in this study should overcome this
problem [32]. Importantly, inclusion of participants aged
30–74 years allowed us to prospectively investigate the
impact of circulating endothelin-1 levels on incident
CHD in a population less confounded by comorbidity.
Another limitation of this study is the lack of infor-
mation regarding menopause in women. Given the
strong interaction between endothelin-1 and NO in
the endothelium, models including determinants of
NO-production should strengthen the results and
might be object of further research.
Conclusion
In conclusion, the results of this prospective study indicate
that endothelin-1 may predict development of CHD in
women. Trials investigating the effect of endothelin-1
receptor antagonists or other means to inhibit endothelin-
1 for prevention of CHD in high-risk women are still lack-
ing and could better address the question of causality.
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